The FDA Pharmacy Compounding Advisory Committee will convene July 23-24, 2026 to consider adding BPC-157, TB-500, KPV, Semax, Epitalon and others to the 503A bulks list. If recommended, compounding pharmacies could legally prepare these compounds for the first time.
More
FDA Reverses Course on Seven Peptides: PCAC Reviews BPC-157, TB-500, KPV in July
What “Research Use Only” Actually Means: The Legal Distinction Researchers and Buyers Keep Conflating
Research use only peptides occupy a narrow legal category that buyers and sellers increasingly treat as a generic disclaimer. As FDA enforcement intensifies in 2026, the RUO line is becoming the dividing line between legitimate laboratory commerce and federal regulatory exposure.
MoreGlow Peptide Research: BPC-157, TB-500, GHK-Cu
Research Hub › Skin & Cosmetic › Glow Peptide Research Research Use Only. The information on this page summarizes published peptide research for laboratory and educational reference. The compounds discussed are intended exclusively for in vitro and non-clinical research. Nothing on this page constitutes medical advice or describes human use, diagnosis, treatment, or therapeutic application. …
More
The Peptide Wild West Hits Mainstream Media: What the Coverage Misses About Research Suppliers
Industry Pulse › The Peptide Wild West Hits Mainstream Media May 3, 2026 · Trends In the last seven days, at least eight major outlets including Fox News, CBS News, The Hill, Medscape, and MDLinx have published variations of the same story: the peptide market is a “Wild West” where unregulated injectables, social-media hype, and …
More
FDA Moves to Ban Compounded Semaglutide and Tirzepatide: What Researchers Need to Know
Industry Pulse › FDA Moves to Ban Compounded Semaglutide and Tirzepatide May 1, 2026 · Regulatory On May 1, 2026, the FDA filed a proposal that would effectively end large-scale compounding of semaglutide, tirzepatide, and liraglutide in the United States. These are the active ingredients in Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Saxenda. If the …
More
Beyond Ozempic and Mounjaro: A Five-Target Obesity Drug Just Outperformed Both
A research team at Helmholtz Zentrum München has published the design of a single-molecule quintuple agonist that activates GLP-1, GIP, and three PPAR receptor subtypes. Published in Nature on April 30, 2026, the conjugate outperformed semaglutide and tirzepatide dual agonism in obese diabetic mouse models.
More